-
Opko Health's Phase 3 Data Sends Stock Plunging
Friday, December 30, 2016 - 11:12am | 266Read More...Shares of Opko Health Inc. (NASDAQ: OPK), a pharmaceutical and diagnostics company, plunged more than 15 percent on Friday after the company reported disappointing results to a clinical trial. In a press release, Opko Health announced data analysis from a Phase 3 trial which evaluated its long-...
-
Opko Health Inks Pfizer License Pact
Monday, December 15, 2014 - 2:49pm | 241Read More...Opko Health Inc. (NYSE: OPK) gained more than 9 percent Monday after the developmental drug company licensed its growth hormone treatment to Pfizer Inc. (NYSE: PFE). Opko will receive a payment of $295 million up front and is eligible to receive up to an additional $275 million if the...
